Related Experiment Video
Updated: May 20, 2026
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Awaiting a new era of cancer immunotherapy
1Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.
Abstract:
A major challenge in cancer therapy is the lack of specificity for cancer cells. Antibody-based therapies have better specificity and, thus, improved efficacy over standard chemotherapy regimens. Monoclonal antibodies (mAb) constitute the most rapidly growing class of human therapeutics and are proven agents for recognizing and destroying malignant cells. However, the development of antibody therapies has focused only on targeting extracellular (cell-surface or secreted) proteins rather than intracellular targets (within cells, such as phosphatases and/or kinases and transcription factors), because antibodies are generally believed to be too large to enter cells, resulting in a large untapped source of intracellular therapeutic targets. Recently, we presented evidence that suggests that intracellular proteins with high expression in cancer cells are useful targets for mAb-based or vaccination immunotherapies, thus challenging current understanding. Here, we further discuss the concept and future uses of these immunotherapies against a large pool of intracellular oncoproteins for cancer therapy. This line of research has the potential to vastly expand the field of antibody therapy and usher in a new era of cancer vaccines.
Insights
Monoclonal antibodies (mAb) can target intracellular cancer proteins, expanding cancer therapy options beyond extracellular targets. This approach opens new avenues for cancer vaccines and antibody-based treatments.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Cancer therapy often lacks specificity, leading to side effects.
- Monoclonal antibodies (mAb) offer improved specificity over chemotherapy.
- Current mAb therapies primarily target extracellular proteins, neglecting intracellular targets.
Purpose of the Study:
- To challenge the notion that antibodies cannot target intracellular proteins.
- To discuss the potential of targeting intracellular oncoproteins for cancer therapy.
- To explore the future applications of mAb-based immunotherapies and cancer vaccines.
Main Methods:
- Reviewing existing evidence on antibody therapy limitations.
- Presenting new evidence supporting intracellular targeting with mAbs.
- Discussing the concept of targeting intracellular oncoproteins.
Main Results:
- Intracellular proteins highly expressed in cancer cells are viable targets for immunotherapy.
- Monoclonal antibodies can be utilized to target these intracellular oncoproteins.
- This approach expands the scope of antibody-based cancer treatments.
Conclusions:
- Targeting intracellular oncoproteins with mAbs represents a significant advancement in cancer therapy.
- This strategy has the potential to broaden the application of antibody therapies.
- It may lead to a new generation of cancer vaccines and treatments.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...